Denis Drygin Net Worth

The estimated Net Worth of Denis Drygin is at least $154 mil dollars as of 1 March 2022. Denis Drygin owns over 76,686 units of Regulus Therapeutics Inc stock worth over $154,000 and over the last 4 years he sold RGLS stock worth over $0. In addition, he makes $0 as Chief Scientific Officer at Regulus Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Denis Drygin RGLS stock SEC Form 4 insiders trading

Denis has made over 2 trades of the Regulus Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 76,686 units of RGLS stock worth $17,638 on 1 March 2022.

The largest trade he's ever made was buying 76,686 units of Regulus Therapeutics Inc stock on 1 March 2022 worth over $17,638. On average, Denis trades about 20,000 units every 5 days since 2020. As of 1 March 2022 he still owns at least 100,000 units of Regulus Therapeutics Inc stock.

You can see the complete history of Denis Drygin stock trades at the bottom of the page.

Denis Drygin biography

Dr. Denis Drygin Ph.D. serves as Chief Scientific Officer of the Company. Dr. Drygin joins Regulus from Pimera, where he was founder and Vice President of Research and Development since 2013. Prior to Pimera, Denis served with Cylene Pharmaceuticals for over 8 years, most recently as Vice President of Biology where he led the initiation of a Phase I clinical trial for CX-5461, supervising development and translation of predictive and prognostic biomarkers. Prior to this, he led biology operations where he oversaw preclinical development of CX-5461, a first-in-class selective inhibitor of Pol I, and the preclinical development program for Silmitasertib, a first-in-class oral inhibitor of Ser/Thr kinase CK2. Prior to Cylene, Denis completed his post-doctoral work at Ionis Pharmaceuticals, where he served as lead scientist on several projects to investigate the pharmacology and toxicology of antisense oligonucleotides (ASOs).

What's Denis Drygin's mailing address?

Denis's mailing address filed with the SEC is C/O REGULUS THERAPEUTICS, 4224 CAMPUS POINT COURT #210, SAN DIEGO, CA, 92121.

Insiders trading at Regulus Therapeutics Inc

Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.

What does Regulus Therapeutics Inc do?

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

Complete history of Denis Drygin stock trades at Regulus Therapeutics Inc

Regulus Therapeutics Inc executives and stock owners

Regulus Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Hagan,
  President, Chief Executive Officer, Director
• Joseph P. Hagan M.B.A.,
  Pres, CEO & Director
• Christopher Aker,
  Senior Vice President, General Counsel
• Christopher Ray Aker J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Crispina Calsada,
  Chief Financial Officer
• Crispina Calsada,
  Chief Financial Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Pascale Witz,
  Independent Director
• Simos Simeonidis,
  Independent Director
• Hugh Rosen,
  Independent Director
• William Rastetter,
  Independent Director
• Jake Nunn,
  Independent Director
• Kathryn Collier,
  Independent Director
• David Baltimore,
  Independent Director
• Denis Drygin,
  Chief Scientific Officer
• Firuz Shakoori,
  Head of CMC
• Turner Jenkins,
  Sr. Director of Corp. Devel.
• Dr. Denis Drygin Ph.D.,
  Chief Scientific Officer
• Daniel J. Penksa,
  Controller & Principal Accounting Officer
• Jason Raleigh Nunn,
  
• Daniel R. Chevallard,
  Chief Financial Officer
• Paul C Grint,
  President & CEO
• Douglas E Williams,
  Director
• Mark Albert Deeg,
  Chief Medical Officer
• Pharmaceuticals, Inc. Alnylam,
  10% owner
• Mark G Foletta,
  Director
• Timothy Michael Wright,
  Chief R & D Officer
• Alexander J Sarissa Capital...,
  
• Plcastrazeneca Ab Astrazeneca,
  
• David Leslie Szekeres,
  Chief Business Officer & GC
• Paul Edward Walker,
  
• Peter J Barris,
  10% owner
• Anthony A. Jr. Florence,
  
• Scott D Sandell,
  
• David M Mott,
  10% owner
• Mohamad Makhzoumi,
  
• Equity Opportunities V, Llc...,
  
• Ali Behbahani,
  
• Neil W Gibson,
  Chief Scientific Officer
• Pharmaceuticals Incparshall...,
  
• Kleanthis G Xanthopoulos,
  President and CEO
• Pharmaceuticals Inc Ionis,
  10% owner
• Bruce L A Carter,
  Director
• Barry E Greene,
  Director
• Sanofi,
  10% owner
• B Lynne Parshall,
  Director
• Stanley T Crooke,
  Director
• John Maraganore,
  Director
• Garry E Menzel,
  COO & Executive VP, Finance
• Forest Baskett,
  
• Carmen Chang,
  
• Joshua Makower,
  
• Peter W. Sonsini,
  
• Capital Offshore Master Fun...,
  10% owner
• Alice Shih Hou Baltimore Da...,
  
• Alice Shih Hou Huang,
  
• Preston Klassen,
  President & Head of R & D